New clinical, laboratory and experimental insights, since the 1999 publication of the
Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been …

Objective To develop new classification criteria for systemic lupus erythematosus ( SLE )
jointly supported by the European League Against Rheumatism ( EULAR ) and the American …

Objective To analyze the clinical and immunologic manifestations of antiphospholipid
syndrome (APS) in a large cohort of patients and to define patterns of disease expression. …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Objective. To assess the true prevalence of con-genital complete heart block (CCHB) in
infants of anti-Ro/SSA–positive women known to have connective tissue disease (CTD) and, …

The impact of autoimmune diseases is growing from both a clinical and a laboratory point of
view. Diagnostic assays are now being transferred from dedicated specialised laboratories …

antibodies concomitant with larger atherosclerotic lesions that contained abundant CD4
cells. OxLDL is the type of LDL that is more likely to undergo uptake by macrophages, which …

Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers of,
antiphospholipid syndrome (APS). Although the presence of aPL is a necessary pre-…

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …